United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. lowered its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 17.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,635 shares of the biotechnology company’s stock after selling 569 shares during the period. E Fund Management Co. Ltd.’s holdings in United Therapeutics were worth $930,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Candriam S.C.A. lifted its position in United Therapeutics by 11.1% during the fourth quarter. Candriam S.C.A. now owns 74,607 shares of the biotechnology company’s stock worth $26,324,000 after buying an additional 7,459 shares during the period. Raymond James Financial Inc. purchased a new position in United Therapeutics during the fourth quarter worth about $18,257,000. Arizona State Retirement System lifted its position in United Therapeutics by 1.6% during the fourth quarter. Arizona State Retirement System now owns 12,267 shares of the biotechnology company’s stock worth $4,328,000 after buying an additional 191 shares during the period. Proficio Capital Partners LLC purchased a new position in United Therapeutics during the fourth quarter worth about $22,658,000. Finally, Seizert Capital Partners LLC lifted its position in United Therapeutics by 3.4% during the fourth quarter. Seizert Capital Partners LLC now owns 40,218 shares of the biotechnology company’s stock worth $14,191,000 after buying an additional 1,312 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity

In other United Therapeutics news, Director Nilda Mesa sold 255 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the sale, the director now owns 5,528 shares in the company, valued at $1,966,696.56. This trade represents a 4.41 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $360.76, for a total value of $3,607,600.00. Following the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at approximately $929,678.52. This trade represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 116,464 shares of company stock worth $42,396,244. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Stock Performance

UTHR stock opened at $315.91 on Friday. United Therapeutics Co. has a 1 year low of $221.53 and a 1 year high of $417.82. The firm has a market cap of $14.19 billion, a P/E ratio of 13.87, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57. The stock has a 50-day simple moving average of $355.41 and a 200-day simple moving average of $360.08.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. During the same quarter last year, the firm earned $4.36 earnings per share. On average, equities research analysts predict that United Therapeutics Co. will post 24.48 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. UBS Group increased their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. Finally, HC Wainwright restated a “buy” rating and issued a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $388.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.